Jatenzo
ApprovedActive 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypogonadism
Conditions
Hypogonadism
Trial Timeline
May 10, 2024 → Mar 1, 2026
NCT ID
NCT06385509About Jatenzo
Jatenzo is a approved stage product being developed by ICON plc. for Hypogonadism. The current trial status is active. This product is registered under clinical trial identifier NCT06385509. Target conditions include Hypogonadism.
What happened to similar drugs?
5 of 18 similar drugs in Hypogonadism were approved
Approved (5) Terminated (3) Active (12)
Hype Score Breakdown
Clinical
20
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06385509 | Approved | Active |
Competing Products
20 competing products in Hypogonadism